Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.

Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.

Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.

Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.

Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.

Abstract: The disclosure relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the disclosure. Also provided herein are methods of treating cancer with the arginase inhibitors of the disclosure.

Abstract: 3-[N-Aroyl(or thioaryol)aminoalkyl]-3-quinuclidinols corresponding to the formula: ##STR1## wherein X is O or S, and Ar is phenyl, substituted phenyl, indole, indazole or pyrimidine; optical isomers and the pharmaceutically acceptable acid addition salts and solvates thereof. These compounds have gastric emptying, antiemetic, anxiolytic and selective serotonin modulating or inhibiting activity.

Abstract: This invention provides 3-quinuclidinyl benzamides which in the form of pharmaceutical compositions have utility as therapeutic agents which exhibit anxiolytic antipsychotic and cognitive improving effects in warm blooded animals.Illustrative of an invention compound is N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-4-dimethylamino-2-hydroxythiobenz amide: ##STR1## or a pharmaceutically acceptable salt thereof.

Abstract: Novel 1-(azabicyclo[2.2.2]oct-3- or -4-yl)benzamides substituted on the benzene ring with the basic substituted aminomethyleneamino group have been found to be useful in treating emesis, including emesis due to chemical and radiation anticancer therapy, anxiety, and impaired gastric emptying. These compounds are represented by Formula I below.

Abstract: N-(1-Substituted-4,5-dihydro-1H-pyrazol-4-yl)benzamides having the general formula: ##STR1## wherein R is loweralkyl, cycloalkyl or phenylloweralkyl and R.sub.1 is selected from hydroxy, cyano, nitro, amino, methylamino, dimethylamino, halo, trifluoromethyl, loweralkyl, loweralkoxy, sulfamoyl or acetamido, and when n is more than 1 up to 3, R.sub.1 can be the same or different, are disclosed as having gastrokinetic and anti-emetic utility in animals and pharmaceutical compositions therefor. A process for preparing the compounds by oxidation of 1,2-disubstituted-N-(4-pyrazolidinyl)benzamides with a metal hypochlorite is disclosed.